Shrujal Baxi Named Chief Medical Officer at Iterative Scopes

Iterative Scopes has welcomed Shrujal Baxi, M.D., into its executive fold, appointing her as chief medical officer.

Baxi specializes in real-world evidence generation, and throughout her career has been involved in multiple clinical trials. In her role as CMO, she will help develop the company’s scientific roadmap and drive forward its mission of using scalable technology and data to advance inflammatory bowel disease (IBD) care and improve patient outcomes.
 
“Having a stellar scientific, medical, and regulatory affairs team is critical to Iterative Scopes’ work, and we’re very excited to have Dr. Baxi leading these groups,” said Jonathan Ng, MBBS, founder and CEO of Iterative Scopes. “As a medical oncologist, Dr. Baxi has witnessed a transformation in oncology that has accelerated the public’s understanding of cancer while also fueling precise management of the disease. Data has driven this innovation and knowledge generation, and I look forward to seeing her apply this expertise to our focus on individualized care for people with inflammatory bowel disease.” 
 
Prior to joining Iterative Scopes, Baxi was senior vice president of Clinical and Scientific Solutions at Verana Health, where she incorporated the voice of the clinician throughout the real-world data (RWD) development process from ingestion through technology-enabled curation and analysis. Before that, she was head of Clinical Science at Flatiron Health, where—using RWD created from electronic health records for regulatory and health-technology-assessment use cases—she focused her time on evidence generation. She also worked with data scientists and engineers to generate high-quality novel datasets.
 
Baxi earned her medical degree from the University of Illinois College of Medicine at Chicago and her master’s degree in public health with an emphasis on health policy and administration from the University of Illinois School of Public Health. After serving as a chief resident at New York University, she completed a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center and joined its faculty in 2011, where she specialized in cancers of the head and neck, salivary glands, and thyroid along with non-melanoma cutaneous malignancies.
 
“I look forward to helping Iterative Scopes tell the story of using data with AI technology’s capabilities—and why it all matters,” Baxi said “Iterative Scopes is advancing the science of gastroenterology and facilitating clinical trials in IBD, and this should be shared and celebrated.”
 
Iterative Scopes applies artificial intelligence-based precision medicine for gastroenterology. Its proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to impact polyp detection for colorectal cancer screenings and working to standardize disease severity characterization for inflammatory bowel disease. Longer term, the company plans to establish more meaningful endpoints for GI diseases, which may be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Mass.